Proxy Votes Now

Home › Funds › State Street › State Street SPDR S&P Pharmaceuticals ETF

State Street SPDR S&P Pharmaceuticals ETF (XPH) proxy voting record 2025-2026

Fund family: State Street · Filed by SPDR SERIES TRUST (CIK 1064642) · SEC series S000012321

Ticker: XPH (C000033537)

“With management” counts the items where the fund’s own filing gives management’s recommendation (FOR or AGAINST): 272 with, 211 against, 0 abstentions (not counted as with management). Shareholder proposals: 0 FOR, 9 AGAINST, 0 abstained, by the filing’s own vote-source field.

Compared with State Street as a whole

The same two figures as State Street’s manager page (773,265 ballot items across 134 funds and accounts), counted the same way for this fund.

2025-2026This fundItemsState StreetItems
Voted FOR the board's own proposals (directors, pay, auditor, capital, transactions, fund matters)92.1%45689.7%592,191
Backed environmental and social shareholder proposals at US companiesn/a46.8%3,767

Where this fund voted differently from most State Street funds

Each ballot item this fund voted is set against the votes of the other State Street funds and accounts on the same item (same meeting, same proposal): “most funds” is a strict majority of at least three of them, FOR against AGAINST, WITHHOLD or ABSTAIN, with split votes and items not voted left out. Funds in one family can follow separate voting policies, for example ESG funds, sub-advised funds and funds using pass-through voting.

Voted the same way as most State Street funds on all 453 items where a comparison was possible.

Votes against management by sector

The same votes as “with management” above, by the sector of the company voted on. 95.7% of this fund’s 483 such votes could be given a sector; the other 21 (4.3%) are at companies without one and are not in the table.

SectorVotesAgainst managementShare
Health Care45120044.3%
Industrials11327.3%

What it voted on

Ballot items by the category the filing put first; “against management” as above.
Proposal typeItemsAgainst management
Director Elections310130
Audit-related6032
Say-on-Pay5931
Compensation2212
Corporate Governance171
Capital Structure122
Extraordinary Transactions40
Shareholder Rights and Defenses31
Environment or Climate22
Other Social Issues20

Its largest holdings’ meetings

Position = shares voted × a recent share price, for US-listed shares of companies with a page on this site; an estimate for ranking only.

CompanyMeetingEst. positionItemsAgainst mgmt
Xeris Biopharma Holdings, Inc.June 4, 2026$17M42
Corcept Therapeutics IncorporatedMay 21, 2026$12M116
Organon & Co.June 9, 2026$12M1312
Viatris Inc.May 15, 2026$11M158
Amneal Pharmaceuticals, Inc.May 6, 2026$11M1211
MBX Biosciences, Inc.June 4, 2026$11M30
Amylyx Pharmaceuticals, Inc.June 4, 2026$10M43
Pacira Biosciences, Inc.June 9, 2026$9M106

Notable votes against management

MeetingCompanyProposalFundMgmt
June 4, 2026Xeris Biopharma Holdings, Inc.To elect two Class II directors to our board of directors to serve until the 2029 Annual Meeting of Stockholders and until his or her successor has been duly elected and qualified, or until his or her earlier death, resignation or removal: John JohnsonForAgainst
June 4, 2026Xeris Biopharma Holdings, Inc.To approve, on a non-binding advisory basis, the compensation of our named executive officers.ForAgainst
May 21, 2026Corcept Therapeutics IncorporatedElection of Directors: Gregg AltonForAgainst
May 21, 2026Corcept Therapeutics IncorporatedElection of Directors: Joseph K. Belanoff, M.D.ForAgainst
June 9, 2026Organon & Co.Election of Directors: Carrie S. CoxForAgainst
June 9, 2026Organon & Co.Election of Directors: Robert EssnerForAgainst
May 15, 2026Viatris Inc.Election of 13 director nominees, each to hold office until the 2027 annual meeting of shareholders: W. Don CornwellForAgainst
May 15, 2026Viatris Inc.Election of 13 director nominees, each to hold office until the 2027 annual meeting of shareholders: JoEllen Lyons DillonForAgainst
May 6, 2026Amneal Pharmaceuticals, Inc.Election of Directors: Deb AutorForAgainst
May 6, 2026Amneal Pharmaceuticals, Inc.Election of Directors: J. Kevin BuchiForAgainst
June 4, 2026Amylyx Pharmaceuticals, Inc.Election of Directors: To elect the following persons to our board of directors, each to serve as a Class II director until the 2029 Annual Meeting of Stockholders and until their successor has been duly elected and qualified, or until such director's earlier death, resignation or removal: George Mclean Milne Jr., Ph.D.ForAgainst
June 4, 2026Amylyx Pharmaceuticals, Inc.Election of Directors: To elect the following persons to our board of directors, each to serve as a Class II director until the 2029 Annual Meeting of Stockholders and until their successor has been duly elected and qualified, or until such director's earlier death, resignation or removal: Paul FonteyneForAgainst

Contested meetings

Meetings with a proxy contest or competing nominees (1 in 2025-2026), and how the fund voted the items on its ballot.

Search this fund’s votes by company

491 ballot items at 62 meetings in 2025-2026. Download all votes (CSV)

Recent notable votes

Recent votes against management’s recommendation at large companies.

About this fund’s record

In the 2025-2026 proxy season, State Street SPDR S&P Pharmaceuticals ETF (XPH) voted at 62 shareholder meetings of 59 companies, on 491 ballot items in all. Where management made a recommendation, the fund followed it on 56.3% of the items and voted against it 211 times. Its most frequent area of disagreement was director elections (130 of its votes against management). It voted on 12 shareholder proposals. It voted FOR the board's own proposals more often than State Street's funds as a whole (92.1% against 89.7%). It voted the same way as most State Street funds on every item where a comparison was possible. 1 of its meetings was contested.

About this page

Every figure is derived from the fund’s own Form N-PX filings with the SEC, read item by item: one ballot item is the fund’s vote on one proposal at one meeting, and an item filed twice in the season is counted once. Percentages count items, never shares. A season is published only with at least 250 ballot items at 15 meetings. Built November 18, 2026; the family figures are those of State Street’s manager page. The interactive database shows the same votes company by company, with every other fund that voted.